IGN 523
Alternative Names: AML-01; anti-CD98 monoclonal antibody; IGN-523Latest Information Update: 28 Jul 2018
Price :
$50 *
At a glance
- Originator Igenica
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD98 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Second-line therapy or greater) in USA (IV, Infusion)
- 28 Feb 2014 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in USA (IV) (NCT02040506)
- 07 Dec 2013 Preclinical trials in Acute myeloid leukaemia in USA (IV) prior to December 2013